442 related articles for article (PubMed ID: 27723254)
1. Leucine-rich repeat kinase 2 and Parkinson's disease.
Kang UB; Marto JA
Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
[TBL] [Abstract][Full Text] [Related]
2. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X; Kortholt A
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 and membrane trafficking: nexus of Parkinson's disease.
Hur EM; Jang EH; Jeong GR; Lee BD
BMB Rep; 2019 Sep; 52(9):533-539. PubMed ID: 31383252
[TBL] [Abstract][Full Text] [Related]
5. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
Nguyen AP; Moore DJ
Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 Phosphorylation.
Nichols RJ
Adv Neurobiol; 2017; 14():51-70. PubMed ID: 28353278
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
[TBL] [Abstract][Full Text] [Related]
9. The Cell Biology of LRRK2 in Parkinson's Disease.
Usmani A; Shavarebi F; Hiniker A
Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 and the Endolysosomal System in Parkinson's Disease.
Erb ML; Moore DJ
J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
[TBL] [Abstract][Full Text] [Related]
11. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Ito G; Utsunomiya-Tate N
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
[TBL] [Abstract][Full Text] [Related]
12. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
Azeggagh S; Berwick DC
Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
15. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
17. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
18. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 activation in idiopathic Parkinson's disease.
Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
